← 返回

早期生长反应因子 1 作为结外 NK/T 细胞淋巴瘤中 PD-L1 表达和免疫逃逸的关键调控因子

英文原题:Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma.

查看英文原题

Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma.

PubMed 2025/06/13(内容时间) Blood Cancer J Q1 · IF 13.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

本研究探讨早期生长反应因子1(EGR1)在结外NK/T细胞淋巴瘤(ENKTL)中的作用及其与PD-L1表达的相关性。对62例ENKTL患者样本的分析显示,EGR1高表达与PD-L1阳性、免疫逃逸-A亚型及早期疾病相关。尽管EGR1表达并非总生存期的独立预后因素,但EGR1水平较高的患者显示出预后较好的趋势。在ENKTL细胞系(YT、SNK6)中,EGR1正向调控LMP1和PD-L1表达。敲低EGR1可降低PD-L1水平,减少PTEN,增加AKT磷酸化,并消除STAT3磷酸化。相反,EGR1过表达可增强PD-L1。组蛋白去乙酰化酶抑制剂恩替诺特处理可上调EGR1和PD-L1,但在EGR1缺失的细胞中该效应消失,表明EGR1是HDAC抑制剂诱导PD-L1表达所必需的。这些发现揭示了EGR1在肿瘤免疫调节中的关键作用,并突出了靶向EGR1、表观遗传调控因子及PD-1/PD-L1检查点的潜在联合治疗策略。

展开英文摘要原文

This study investigates the role of Early Growth Response 1 (EGR1) in extranodal natural killer/T-cell lymphoma (ENKTL) and its correlation with PD-L1 expression. Analysis of 62 ENKTL patient samples revealed that high EGR1 expression was linked to PD-L1 positivity, the immune evasion-A subtype, and early-stage disease. Although EGR1 expression was not an independent prognostic factor for overall survival, patients with higher EGR1 levels showed a trend toward better outcomes.

In ENKTL cell lines (YT, SNK6), EGR1 positively regulated LMP1 and PD-L1 expression. Knockdown of EGR1 reduced PD-L1 levels, decreased PTEN, increased AKT phosphorylation, and abrogated STAT3 phosphorylation. Conversely, EGR1 overexpression enhanced PD-L1. Treatment with the histone deacetylase inhibitor entinostat upregulated both EGR1 and PD-L1, but this effect was lost in EGR1-depleted cells, indicating EGR1's necessity for HDAC inhibitor-induced PD-L1 expression.

These findings reveal EGR1's pivotal role in tumor immune modulation and highlight potential combination therapies targeting EGR1, epigenetic regulators, and PD-1/PD-L1 checkpoints.

论文信息

作者
Lee JY、Kim KJ、Park W、Seo J、Kang M、Jung EH、Kim SA、Suh KJ
第一作者单位
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.South Korea
通讯作者单位
Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. paikjh@snubh.org.South Korea
期刊
Blood cancer journal2025 Jun 13
原文标识
PubMed 40514360 · DOI 10.1038/s41408-025-01313-w